CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 132 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,447,421 | -9.3% | 706,665 | +11.9% | 2.27% | -5.6% |
| Q2 2023 | $21,432,393 | +20.1% | 631,665 | +27.4% | 2.41% | -11.3% |
| Q1 2023 | $17,839,712 | +80626.3% | 495,823 | 0.0% | 2.72% | -18.4% |
| Q4 2022 | $22,099 | -99.9% | 495,823 | -8.0% | 3.33% | +36.8% |
| Q3 2022 | $15,146,000 | +4.3% | 538,812 | 0.0% | 2.44% | -20.7% |
| Q2 2022 | $14,526,000 | +76.8% | 538,812 | +123.4% | 3.07% | +67.4% |
| Q1 2022 | $8,215,000 | -38.7% | 241,199 | -2.8% | 1.84% | -48.1% |
| Q3 2021 | $13,401,000 | +23.9% | 248,207 | -23.3% | 3.53% | -6.2% |
| Q2 2021 | $10,816,000 | +41.9% | 323,437 | -12.6% | 3.77% | +24.1% |
| Q1 2021 | $7,621,000 | +22.0% | 369,951 | +3.8% | 3.04% | -10.6% |
| Q4 2020 | $6,245,000 | – | 356,431 | – | 3.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |